### Sofosbuvir

**Indication**: Chronic hepatitis C  
**ICD11 code**: E91.1

**InN**: Sofosbuvir

**Medicine type**: Chemical agent

**List type**: Core (EML) (EMLc)

**Additional notes**: Pangenotypic when used in combination with daclatasvir or ravidasvir.

**Formulations**: Oral > Solid > tablet: 200 mg; 400 mg

**EML status history**:
- First added in 2015 (TRS 994)
- Changed in 2019 (TRS 1021)
- Changed in 2021 (TRS 1035)
- Changed in 2023 (TRS 1049)

**Sex**: All

**Age**: Also recommended for children

**Therapeutic alternatives**: Medicines within the same pharmacological class can be used

**Therapeutic alternatives limitations**: Pangenotypic direct-acting antiviral combinations

**Therapeutic alternatives limitations for EMLc**: Pangenotypic direct-acting antiviral combinations

**Patent information**: Main patent is active in several jurisdictions. For more information on specific patents and license status for developing countries visit [www.MedsPal.org](http://www.MedsPal.org)

**Wikipedia**: [Sofosbuvir](http://en.wikipedia.org/wiki/Sofosbuvir)

**DrugBank**: [Sofosbuvir](http://www.drugbank.ca/drugs/DB01979)

---

### Summary of evidence and Expert Committee recommendations

The note associated with the listing of sofosbuvir was updated following the recommendation to include ravidasvir on the EML.